Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.
about
Creatine for Parkinson's diseaseLinked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatmentsPioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month resultsEffect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease.Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trialSeniors with Parkinson's disease: initial medical treatment.Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.The futility study--Progress over the last decade.Advances in designs for Alzheimer's disease clinical trials.Study in Parkinson disease of exercise (SPARX): translating high-intensity exercise from animals to humansOptimal frequency for measuring health care resource utilization in Parkinson's disease using participant recall: the FS-TOO resource utilization substudy.Targets for neuroprotection in Parkinson's diseaseDevelopmental susceptibility of neurons to transient tetrahydrobiopterin insufficiency and antenatal hypoxia-ischemia in fetal rabbits.Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial.Overcoming obstacles in Parkinson's disease.The promise of futility trials in neurological diseases.Emtonjeni-A Structural Intervention to Integrate Sexual and Reproductive Health into Public Sector HIV Care in Cape Town, South Africa: Results of a Phase II Study.Combination therapies for traumatic brain injury: prospective considerations.Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States.Clinician-trialist rounds: 18. Should young (and old!) clinician-trialists perform single-arm Phase II futility trials?Design of phase II ALS clinical trials.Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials.
P2860
Q24193947-EBE8E57A-FAE8-4713-9F32-DC5654A9E910Q26995786-7E285C5E-25D0-4157-B06F-EB1F369379C6Q30357397-D29B916E-A1BA-407D-B38E-9355525E7551Q30407150-9E694495-61AB-46F8-AD83-4DADA9CAA232Q30407589-84ADD9E1-DF6A-462A-B9F9-5DE3E5E05D1DQ30431912-A8BC4D7F-4ED1-4924-A877-75F0E7259A6DQ33964112-640E5567-AB46-4E41-93CB-711341A71D10Q34508143-8E52F8A5-A684-497C-AA64-202A5896791BQ34658560-A3947B5E-ADFC-4453-AEBF-AFE2FD238587Q36264697-6522B8C6-F5A6-424E-8900-145D13085557Q36576472-C906E8CD-6297-4DB1-9775-5EB7A19A1369Q37161380-72DE9EBB-2808-47AF-95D1-DA7BD2E80686Q37172826-7303CD93-9446-497F-AD61-DBE4631487EFQ37302453-B81926C6-4D39-459A-AB9E-CFA2E496EF6AQ37622166-81F27D68-7213-43AC-9601-33AE75BA4CD3Q37675595-5C7C591A-5C29-4BC3-AB2C-466A3E637E89Q38056875-5D74DC01-10A3-45ED-81C8-BBED628EEF61Q38380170-992840FC-B440-4689-A7B6-E48A0AC0E41BQ40494176-703E08A5-32C2-4245-B3F6-A08D793F2751Q42616360-9C02EB53-A356-40DD-89DD-4A9FAF6F08C4Q46823146-C733B383-4023-4FEA-8F93-048FD94E6286Q50073420-A3683B92-37AF-4B1D-9F9B-1187E84BABFDQ51158231-9023C506-5939-46E9-AE04-925A9CE6C0B4Q53220635-D8587F18-2DA5-4A9A-9870-F3CD2A5D10C8Q55112408-C0F3547D-33F8-44D2-AB82-791430B46D23
P2860
Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Optimizing the ongoing search ...... sease: using futility designs.
@ast
Optimizing the ongoing search ...... sease: using futility designs.
@en
type
label
Optimizing the ongoing search ...... sease: using futility designs.
@ast
Optimizing the ongoing search ...... sease: using futility designs.
@en
prefLabel
Optimizing the ongoing search ...... sease: using futility designs.
@ast
Optimizing the ongoing search ...... sease: using futility designs.
@en
P2093
P1433
P1476
Optimizing the ongoing search ...... sease: using futility designs.
@en
P2093
B C Tilley
C M Tanner
G F Wooten
K Kieburtz
NET-PD Investigators
P304
P356
10.1212/01.WNL.0000201251.33253.FB
P407
P577
2006-03-01T00:00:00Z